OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLC

October 24th 2024

Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.

Dr Gordon on the Clinical Implications of the TRANSCEND NHL 001 Trial of Liso-Cel in R/R MCL

October 24th 2024

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate Cancer

October 24th 2024

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

Dr Drilon on Efficacy Results With Taletrectinib in ROS1+ NSCLC

October 23rd 2024

Alexander Drilon, MD, discusses efficacy findings from the TRUST-I and TRUST-II trials in patients with ROS1+ non–small cell lung cancer.

Dr Rimm on Limitations With IHC Testing in HER2-Low and HER2-Ultralow Breast Cancer

October 23rd 2024

David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.

Dr Foster on Daratumumab/Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma

October 23rd 2024

Laahn Ho Foster, MD, discusses the potential role of daratumumab plus lenalidomide maintenance in multiple myeloma after ASCT.

Dr Fisher on Mechanisms of Resistance with Covalent BTK Inhibitors in CLL

October 23rd 2024

David C. Fisher, MD, discusses resistance mechanisms observed among patients with CLL who were previously treated with covalent BTK inhibitors.

Dr Ducreux on the Potential Use of Liver Transplantation Plus Chemo for CRC Liver Metastases

October 23rd 2024

Michel Ducreux, MD, PhD, discusses the rationale for the TRANSMET trial in patients with CRC liver metastases, highlighting the significance of data from the trial.

Dr Dimopoulos on Patient Reported Outcomes With BPd in Pretreated R/R Multiple Myeloma

October 23rd 2024

Meletios A. Dimopoulos, MD, discusses patient-reported outcomes with BPd in pretreated patients with relapsed/refractory multiple myeloma.

Dr Friedlander on the Design and Methods of the Duravelo-2 Trial in Urothelial Cancer

October 23rd 2024

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Dr Mazzoni on the Use of Quadruplet Regimens in Newly Diagnosed Myeloma

October 23rd 2024

Sandra Mazzoni, DO, discusses the emerging role of quadruplet regimens in newly diagnosed multiple myeloma.

Dr Dhakal on the Design of the CARTITUDE-4 Study in R/R Myeloma

October 23rd 2024

Binod Dhakal, MD, discusses the design of the CARTITUDE-4 study investigating cilta-cel in relapsed/refractory multiple myeloma.

Dr Cortes on the Phase 4 BYOND Study in Previously Treated Patients With CML

October 21st 2024

Jorge E. Cortes, MD, discusses efficacy and safety findings from the phase 4 BYOND study in previously treated patients with Ph+ chronic myeloid leukemia.

Dr Girard on Findings From the LUMINOSITY Trial in c-Met–Overexpressing NSCLC

October 21st 2024

Nicolas Girard, MD, discusses finding from the LUMINOSITY trial in c-Met protein–overexpressing, EGFR wild-type, non–small cell lung cancer.

Dr Adige on Improving QOL Post–Breast Cancer Treatment

October 21st 2024

Sunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.

Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibitors in AML Management

October 21st 2024

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ Adenocarcinoma

October 18th 2024

Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

Dr Corre on the Clinical Implications of D-VTd Treatment in Newly Diagnosed Myeloma

October 18th 2024

Jill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Dr Tang on Unanswered Questions About the Role of Radiation Therapy in RCC

October 18th 2024

Chad Tang, MD, discusses unanswered questions surrounding the role of radiation therapy in renal cell carcinoma.

Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL

October 17th 2024

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.